Key Points Moderna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough. This product could rival the lifetime sales of Moderna's coronavirus vaccine. Moderna's deep pipeline makes the stock even more attractive. 10 stocks we like better than Moderna › Moderna (NASDAQ: MRNA) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies. This new product should meaningfully contribute to the biotech's financial results over the medium term.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。